Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606582 | 1.00 | ACHE (0.52) | ACHEBACE1ROCK2KMT2AMEN1 | |
| SCHEMBL3598549 | 0.84 | KDM4E (0.59) | KMT2AMEN1MLLT1 | |
| SCHEMBL3598547 | 0.84 | KDM4E (0.59) | KMT2AMEN1MLLT1 | |
| SCHEMBL3609392 | 0.81 | HRH4 (0.58) | KMT2AMEN1POLB | |
| SCHEMBL3608650 | 0.81 | HDAC3 (0.49) | ACHEROCK2KMT2AMEN1POLB | |
| SCHEMBL3609388 | 0.81 | HRH4 (0.58) | KMT2AMEN1POLB | |
| SCHEMBL3608646 | 0.81 | HDAC3 (0.49) | ACHEROCK2KMT2AMEN1POLB | |
| SCHEMBL3602723 | 0.81 | GHSR (0.61) | POLBGHSRMLLT1 | |
| SCHEMBL3602728 | 0.81 | GHSR (0.61) | POLBGHSRMLLT1 | |
| SCHEMBL3603886 | 0.80 | HRH4 (0.56) | ROCK2KMT2AMEN1POLBGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | ACHE 1813/4885BACE1 3608/4885ROCK2 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.